ROCHE HOLDING LTD S/ADR (RHHBY)
RHHBY moved a median of +0.03% 30 minutes after news, and 0.00% by the close. How RHHBY actually reacts to news — the realized, point-in-time move the market made, measured across 449 labeled events over the last three years with zero look-ahead.
RHHBY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.03% | 55% | 449 |
| 30-min | +0.03% | 52% | 449 |
| 60-min | +0.01% | 51% | 449 |
| to close | 0.00% | 48% | 449 |
| Middle 50% of RHHBY reactions | -0.21% to +0.24% |
|---|---|
| Median reaction (30-min) | +0.03% |
| Measured reactions | 449 |
Half of all ROCHE HOLDING LTD S/ADR news events land between -0.21% and +0.24% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RHHBY reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 17 | +0.04% | 65% | -0.04% |
| Analyst downgrades | 12 | +0.13% | 58% | -0.23% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how RHHBY ranks against every other measured name →
That’s how RHHBY usually reacts — get an email when it moves on news →Email me when RHHBY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RHHBY's baseline. Nothing else.
Recent RHHBY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss | Press release | Business Wire | — | — | |
| FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer | Press release | Business Wire | -0.04% | +0.48% | |
| Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC | Press release | PR Newswire | -0.18% | +1.24% | |
| Flatiron Health's Breast Cancer Panoramic Dataset Surpasses One Million Patients, Enabling Real-World Research at Unprecedented Scale | Press release | Business Wire | -0.02% | -0.27% | |
| Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends | Press release | Business Wire | -0.02% | -0.27% | |
| Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions | Press release | Business Wire | -0.02% | -0.27% | |
| Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine | Press release | Business Wire | -0.02% | -0.27% | |
| Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis | Press release | Business Wire | -0.32% | -1.37% | |
| Roche launches newborn screening test for three severe genetic conditions | Press release | PR Newswire | -0.32% | -1.37% | |
| Flatiron Health Expands Global Panoramic Datasets With AI-Powered Breast Cancer and NSCLC Real-World Data for the UK, Germany, and Japan | Press release | Business Wire | +0.30% | -0.34% | |
| Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon | Press release | Business Wire | +0.30% | -0.34% | |
| Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN) | Press release | Business Wire | +0.34% | -1.01% | |
| Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity | Press release | Business Wire | -0.29% | +1.22% | |
| Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center | Press release | Business Wire | +0.04% | -0.23% | |
| Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study | Press release | Business Wire | +0.00% | +0.31% | |
| U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments | Press release | Business Wire | +0.18% | +0.38% | |
| NCCN and Flatiron Health Announce Renewal of Collaboration to Advance Real-World Data Research Across Leading Cancer Centers | Press release | Business Wire | +0.04% | -1.28% | |
| Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors | Press release | Business Wire | +0.17% | -1.44% | |
| Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore | Press release | PR Newswire | -0.42% | -2.10% | |
| Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA | Press release | PR Newswire | -0.04% | -0.32% | |
| Flatiron Health Expands NSCLC Panoramic Dataset With Comprehensive Biomarker Data Model, Enabling Precision Medicine Research at Unprecedented Scale | Press release | Business Wire | +0.04% | +1.16% | |
| Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care | Press release | PR Newswire | +0.05% | -0.02% | |
| Genentech Announces Manufacturing Expansion in Hillsboro, Oregon | Press release | Business Wire | +0.21% | -1.14% | |
| Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility | Press release | Business Wire | +0.04% | +0.04% | |
| Roche expands cyclospora testing portfolio to support U.S. public health response | Press release | PR Newswire | -0.07% | -1.06% | |
| Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis | Press release | PR Newswire | -0.55% | +0.40% | |
| Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow challenges | Press release | PR Newswire | -0.37% | -0.21% | |
| Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America | Press release | PR Newswire | -0.04% | -1.10% | |
| FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy | Press release | Business Wire | +0.06% | +1.43% | |
| Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC | Press release | Business Wire | +0.15% | -0.95% | |
| Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer | Press release | Business Wire | +0.19% | +1.47% | |
| FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED) | Press release | Business Wire | -0.14% | -0.96% | |
| FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma | Press release | Business Wire | -0.18% | -1.39% | |
| FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer | Press release | Business Wire | +0.04% | +0.65% | |
| Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies | Press release | PR Newswire | +0.04% | +0.65% | |
| Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection | Press release | PR Newswire | +0.13% | -0.05% | |
| FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting | Press release | Business Wire | +0.02% | -0.41% | |
| U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation | Press release | Business Wire | +0.02% | -0.41% | |
| Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions | Press release | Business Wire | -0.35% | -2.07% | |
| Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026 | Press release | Business Wire | +0.15% | +0.78% | |
| New Research Confirms Data Quality as the Defining Priority Across the Real-World Evidence Landscape | Press release | Business Wire | +0.39% | +0.37% | |
| Flatiron Health Launches Flatiron Telescope, a New AI Platform Delivering Oncology Insights in Minutes | Press release | Business Wire | -0.15% | +0.32% | |
| Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer | Press release | Business Wire | -0.15% | +0.32% | |
| FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment | Press release | Business Wire | -0.04% | -0.04% | |
| Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026 | Press release | Business Wire | +0.04% | +0.83% | |
| Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign | Press release | Business Wire | -0.06% | +0.94% | |
| Flatiron Health Announces 18 Research Acceptances Featuring Flatiron's Real-World Data to Be Presented at ISPOR 2026 | Press release | Business Wire | +0.06% | +2.05% | |
| FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus | Press release | Business Wire | -0.65% | -2.02% | |
| Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD | Press release | Business Wire | -0.16% | -1.77% | |
| Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS | Press release | Business Wire | +0.06% | +2.05% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RHHBY section they belong to.
Where else RHHBY is measured.
RHHBY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Glaukos Corporation (GKOS) | 452 | +0.04% | 51% |
| Cosmos Health Inc. (COSM) | 450 | 0.00% | 50% |
| CareDx, Inc. (CDNA) | 443 | -0.11% | 47% |
| Arvinas, Inc. (ARVN) | 442 | -0.26% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ROCHE HOLDING LTD S/ADR's median reaction calculated?
Every labeled RHHBY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 449 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of RHHBY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RHHBY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.